For the first time in its history, the US Food and Drug Administration has approved a medication for the pre-surgical (neoadjuvant) treatment of early-stage (I, II) breast cancer.

HER2 is a protein that can be overexpressed in breast cancer, causing an aggressive disease. While there are treatments that target HER2, this form of cancer is tenacious. Scientists have found a new treatment option for this type of breast cancer.

Women who are at high risk of developing breast cancer may be prescribed risk-reducing medications. Because some of these medicines have serious side effects, recommendations regarding who should take them have changed.

It’s not unusual for elderly individuals to have trouble with day-to-day activities. The addition of cancer treatments may make these tasks an even greater struggle, according to new research.

Is more radiation therapy better? A group of UK researchers hoped to answer that question with recently published research.

You may recall that Angelina Jolie recently had a double mastectomy to reduce her risks of developing breast cancer. Researchers have discovered that young women are opting for similar operations to protect themselves.

Mistakes in the BRCA1 gene can increase a woman’s risk of both breast and ovarian cancer. This reality is well-established. What hasn’t been clear is if BRCA carriers are more likely to die from their cancers than are women without the altered genes. A new study offers good news.

After a lumpectomy (removal of breast tumor), breast cancer patients usually have radiation therapy to kill any remaining cancer cells. There are two main types of radiation therapy — one that treats the whole breast and one that treats part of the breast. Which is more effective?